Over 40 Phase 2 and Phase 3 clinical trials were used in training this model, spanning 13 distinct therapeutic agents from 7 drug classes, including THF inhibitors, T&B cell inhibitors, JAK inhibitors, and IL-6 inhibitors across patients with inadequate response to methotrexate and patients with inadequate response to TNF inhibitors.